ACCEPTED MANUSCRIPT
[3] J. Gräff, L.-H. Tsai, The potential of HDAC inhibitors as cognitive enhancers, Annu. Rev.
Pharmacol. Toxicol., 53 (2013) 311-330.
[4] K. Halkidou, L. Gaughan, S. Cook, H. Y. Leung, D. E. Neal, C. N. Robson, Upregulation and
nuclear recruitment of HDAC1 in hormone refractory prostate cancer, Prostate, 59 (2004)
177-189.
[5] A. Abbas, S. Gupta, The role of histone deacetylases in prostate cancer, Epigenetics, 3 (2008)
300-309.
[6] E. Noonan, R. Place, D. Pookot, S. Basak, J. Whitson, H. Hirata, C. Giardina, R. Dahiya,
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer, Oncogene, 28 (2009)
1714-1724.
[7] M. Kirschbaum, P. Frankel, L. Popplewell, J. Zain, M. Delioukina, V. Pullarkat, D. Matsuoka, B.
Pulone, A. J. Rotter, I. Espinoza-Delgado, Phase II study of vorinostat for treatment of relapsed
or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma, J. Clin. Oncol., 29
(2011) 1198-1203.
[8] L. M. Butler, D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H. T. Thaler, R. A.
Rifkind, P. A. Marks, V. M. Richon, Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Res., 60
(2000) 5165-5170.
[9] V. Lakshmikanthan, I. Kaddour, Djebbar, R. W. Lewis, M. V. Kumar, SAHA-sensitized prostate
cancer cells to TNFα-related apoptosis inducing ligand (TRAIL): Mechanisms leading to
synergistic apoptosis, Int. J. Can., 119 (2006) 221-228.
[11] G. L. Gravina, F. Marampon, I. Giusti, E. Carosa, S. D. Sante, E. Ricevuto, V. Dolo, V.
Tombolini, E. A. Jannini, C. Festuccia, Differential effects of PXD101 (belinostat) on
androgen-dependent and androgen-independent prostate cancer models, Int. J. Oncol., 40 (2012)
711.
[12] G. L. Gravina, F. Marampon, P. Muzi, A. Mancini, M. Piccolella, P. Negri-Cesi, M. Motta, A.
Lenzi, E. Di Cesare, V. Tombolini, PXD101 potentiates hormonal therapy and prevents the onset
of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical
models of prostate cancer, Endocr. Relat. Cancer, 20 (2013) 321-337.
[13] (a) Y. Zhang, P. Yang, C. J. Chou, C. Liu, X. Wang, W. Xu, Development of
N-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap
group, ACS Med. Chem.Lett., 4 (2013) 235-238. (b) S. Mehndiratta, Y. L. Hsieh, Y. M. Liu, A.
W. Wang, H. Y. Lee, L. Y. Liang, S. Kumar, C. M. Teng, C. R. Yang, J. P. Liou,
Indole-3-ethylsulfamoylphenylacrylamides: Potent histone deacetylase inhibitors with
anti-inflammatory activity, Eur. J. Med. Chem., 85 (2014) 468-479. (c) Y. C. Huang, F. I. Huang,
S. Mehndiratta, S. C. Lai, J. P. Liou, C. R. Yang, Anticancer activity of MPT0G157, a derivative
of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis, Oncotarget, 6 (2015)
18590-18601. (d) S. Mehndiratta, S. L. Pan, S. Kumar, J. P. Liou,
Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti-proliferative and Anti-angiogenic
Activities” Anticancer Agents Med. Chem., 16 (2016), 907-913.
[14] Y. S. Cho, L. Whitehead, J. Li, C. H. -T. Chen, L. Jiang, M. Vögtle, E. Francotte, P. Richert, T.
Wagner, M. Traebert, Conformational refinement of hydroxamate-based histone deacetylase
inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824), J. Med.
Chem., 53 (2010) 2952-2963.
[15] T. A. Miller, D. J. Witter, S. Belvedere, Histone deacetylase inhibitors, J. Med. Chem., 46
(2003) 5097-5116.
[16] Y. Guo, J. Xiao, Z. Guo, F. Chu, Y. Cheng, S. Wu, Exploration of a binding mode of indole
amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses, Bioorg.
Med.Chem., 13 (2005) 5424-5434.
24